Kiyotaka Uchiyama
Kiyotaka Uchiyama has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
Naoki Washida
24 shared publicationsHiroshi Itoh
23 shared publicationsKohkichi Morimoto
17 shared publicationsTakashin Nakayama
17 shared publicationsEi Kusahana
12 shared publicationsTakahiro Kasai
11 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 12 (1)
Association between annual hemoglobin variability and thromboembolism risk in patients on hemodialysis: a retrospective cohort study in Japan
Background: Hemoglobin levels fluctuate in patients on hemodialysis, and a rapid increase in hemoglobin may trigger thromboembolism. However, the association between annual variability in hemoglobin levels and thromboembolism in patients on hemodialysis remains unclear. Methods: This multicenter, retrospective cohort study included 307 patients (202 males) who underwent continuous hemodialysis at one of the three Shibagaki Clinics (Jiyugaoka, Togoshi, and Kugahara) from April 2019 to March 2020. The mean age was 70.0 ± 12.5 years, and the median hemodialysis duration was 5.1 years. Annual hemoglobin variability was defined as the standard deviation of hemoglobin levels, calculated from monthly predialysis hemoglobin values over a 1-year period. During the observation period from April 2020 to March 2023, the primary outcome was the association between hemoglobin variability and the incidence of thromboembolism (acute coronary syndrome, cerebral infarction, and vascular access thrombosis), and the secondary outcomes were major adverse cardiovascular events (MACEs) and all-cause hospitalization, evaluated using the Cox regression analysis. Results: The mean annual hemoglobin variability was 0.76 ± 0.32 g/dL. Patients were classified into three groups on the basis of hemoglobin standard deviation tertiles. By log-rank test, the patients with high hemoglobin variability had significantly lower rates of thromboembolism-free survival ( P < 0.001) and all-cause hospitalization-free survival ( P = 0.034), compared with those with low hemoglobin variability. By Cox regression analysis adjusted for age, sex, hemodialysis duration, comorbidities, mean annual hemoglobin level, and other dialysis-related parameters, greater hemoglobin variability was significantly associated with a higher risk of thromboembolism (hazard ratio [HR], 3.84; 95% confidence interval [CI], 2.03–7.28, P < 0.001), MACEs (HR, 1.92; 95% CI 1.02–3.61; P = 0.044), and all-cause hospitalization (HR, 1.64; 95% CI 1.08–2.50; P = 0.022). Sensitivity analysis using the subdistribution hazard model yielded results similar to those observed for the primary outcome (subdistribution HR, 4.70; 95% CI 2.50–8.83; P < 0.001). Conclusions: In Japanese patients on hemodialysis, a greater mean annual hemoglobin variability was associated with thromboembolism, MACEs, and all-cause hospitalization. Further studies are warranted to investigate whether reducing annual hemoglobin variability can aid in mitigating thromboembolic events in patients on hemodialysis.
- 18 March 2026
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 12 (1)
Open AccessAssociation between annual hemoglobin variability and thromboembolism risk in patients on hemodialysis: a retrospective cohort study in Japan
Background: Hemoglobin levels fluctuate in patients on hemodialysis, and a rapid increase in hemoglobin may trigger thromboembolism. However, the association between annual variability in hemoglobin levels and thromboembolism in patients on hemodialysis remains unclear. Methods: This multicenter, retrospective cohort study included 307 patients (202 males) who underwent continuous hemodialysis at one of the three Shibagaki Clinics (Jiyugaoka, Togoshi, and Kugahara) from April 2019 to March 2020. The mean age was 70.0 ± 12.5 years, and the median hemodialysis duration was 5.1 years. Annual hemoglobin variability was defined as the standard deviation of hemoglobin levels, calculated from monthly predialysis hemoglobin values over a 1-year period. During the observation period from April 2020 to March 2023, the primary outcome was the association between hemoglobin variability and the incidence of thromboembolism (acute coronary syndrome, cerebral infarction, and vascular access thrombosis), and the secondary outcomes were major adverse cardiovascular events (MACEs) and all-cause hospitalization, evaluated using the Cox regression analysis. Results: The mean annual hemoglobin variability was 0.76 ± 0.32 g/dL. Patients were classified into three groups on the basis of hemoglobin standard deviation tertiles. By log-rank test, the patients with high hemoglobin variability had significantly lower rates of thromboembolism-free survival ( P < 0.001) and all-cause hospitalization-free survival ( P = 0.034), compared with those with low hemoglobin variability. By Cox regression analysis adjusted for age, sex, hemodialysis duration, comorbidities, mean annual hemoglobin level, and other dialysis-related parameters, greater hemoglobin variability was significantly associated with a higher risk of thromboembolism (hazard ratio [HR], 3.84; 95% confidence interval [CI], 2.03–7.28, P < 0.001), MACEs (HR, 1.92; 95% CI 1.02–3.61; P = 0.044), and all-cause hospitalization (HR, 1.64; 95% CI 1.08–2.50; P = 0.022). Sensitivity analysis using the subdistribution hazard model yielded results similar to those observed for the primary outcome (subdistribution HR, 4.70; 95% CI 2.50–8.83; P < 0.001). Conclusions: In Japanese patients on hemodialysis, a greater mean annual hemoglobin variability was associated with thromboembolism, MACEs, and all-cause hospitalization. Further studies are warranted to investigate whether reducing annual hemoglobin variability can aid in mitigating thromboembolic events in patients on hemodialysis.
- Open Access
- 31 December 2025
- Published by Elsevier in Kidney International Reports
- Vol. 11 (3) , 103761
Response to the Letter to the Editor Entitled “SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes”
- 31 December 2025
- Published by Elsevier in Kidney International Reports
- Vol. 11 (3) , 103761
Open AccessResponse to the Letter to the Editor Entitled “SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes”
- 16 May 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (7) , 2505-2506
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]
- 16 May 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (7) , 2505-2506
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]
- Open Access
- 17 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (6) , 1864-1873
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5
- 17 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (6) , 1864-1873
Open AccessKidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5
- Open Access
- 18 January 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (4) , 1063-1075
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
- 18 January 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (4) , 1063-1075
Open AccessOpen-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
- 6 December 2024
- Published by S. Karger AG in Blood Purification
- Vol. 54 (3) , 174-183
Early Initiation of Icodextrin Reduces Peritoneal Dialysis-Associated Peritonitis Risk: A Retrospective Cohort Study
Introduction: Peritonitis is a common and serious complication of peritoneal dialysis (PD) that leads to its discontinuation and death. Icodextrin (ICO) improves peritoneal ultrafiltration and its early use reduces mortality. However, its effectiveness in reducing PD-associated infections remains to be elucidated. Methods: This retrospective observational study enrolled patients who underwent PD between September 2011 and March 2020. The patients were classified into two groups: those who received ICO at the initiation of PD therapy (early ICO) and those who received ICO later or not at all (late/no ICO) and were followed up from PD induction until PD cessation, death, or 3 years had passed. Results: Of the 82 patients (age, 61 [53–72] years), 21 received early ICO. During follow-up (36 [14–36] months), the incidence of PD-associated peritonitis was 0.17 episodes per patient-year. Log-rank tests indicated that PD-associated peritonitis and tunnel infection (TI)-free survival rates were significantly better with the early use of ICO than with late/no ICO (p = 0.02 and p = 0.01, respectively). The early use of ICO remained significantly associated with decreased incidence of both peritonitis and TI (hazard ratio [HR], 0.19; 95% confidence interval [CI], 0.06–0.69 and HR, 0.10; 95% CI, 0.01–0.78, respectively) using Cox regression analysis adjusted for potential confounders. Conclusion: Beginning ICO administration at the initiation of PD shows promise for mitigating the risks of PD-associated peritonitis and TI.
- 6 December 2024
- Published by S. Karger AG in Blood Purification
- Vol. 54 (3) , 174-183
Early Initiation of Icodextrin Reduces Peritoneal Dialysis-Associated Peritonitis Risk: A Retrospective Cohort Study
Introduction: Peritonitis is a common and serious complication of peritoneal dialysis (PD) that leads to its discontinuation and death. Icodextrin (ICO) improves peritoneal ultrafiltration and its early use reduces mortality. However, its effectiveness in reducing PD-associated infections remains to be elucidated. Methods: This retrospective observational study enrolled patients who underwent PD between September 2011 and March 2020. The patients were classified into two groups: those who received ICO at the initiation of PD therapy (early ICO) and those who received ICO later or not at all (late/no ICO) and were followed up from PD induction until PD cessation, death, or 3 years had passed. Results: Of the 82 patients (age, 61 [53–72] years), 21 received early ICO. During follow-up (36 [14–36] months), the incidence of PD-associated peritonitis was 0.17 episodes per patient-year. Log-rank tests indicated that PD-associated peritonitis and tunnel infection (TI)-free survival rates were significantly better with the early use of ICO than with late/no ICO (p = 0.02 and p = 0.01, respectively). The early use of ICO remained significantly associated with decreased incidence of both peritonitis and TI (hazard ratio [HR], 0.19; 95% confidence interval [CI], 0.06–0.69 and HR, 0.10; 95% CI, 0.01–0.78, respectively) using Cox regression analysis adjusted for potential confounders. Conclusion: Beginning ICO administration at the initiation of PD shows promise for mitigating the risks of PD-associated peritonitis and TI.
- 17 October 2024
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 45 (4) , 204-213
Impact of home-based exercise on residual kidney function in patients initiating peritoneal dialysis: A feasibility multicenter randomized controlled trial
Background: Although the impact of aerobic exercise (AE) and resistance training (RT) on peritoneal dialysis (PD) patients is well established, the impact of exercise programs on residual kidney function (RKF) has not been elucidated. Methods: Patients were randomly assigned to either the exercise ( n = 25) or control groups ( n = 30). Patients in the exercise group performed AE three times a week and RT twice a week at home for 24 weeks. The control group did not receive any specific intervention. The primary outcome was RKF, assessed by residual glomerular filtration rate (rGFR). Secondary outcomes included urinary protein levels, distance covered in the incremental shuttle walking test (ISWT), and glycated hemoglobin (HbA1c) percentages. Results: Linear mixed-effects models showed no significant changes in mean rGFR between the exercise and control groups at 12 weeks (−0.40; 95% confidence interval (CI): −2.17, 1.36; p = 0.65) and at 24 weeks (0.65; 95% CI: −1.15, 2.45; p = 0.48). There was a trend toward improvement in mean urinary protein level and ISWT results, and a significant decrease in mean HbA1c percentage at 24 weeks in the exercise group (−1.07, 95% CI: −2.29, 0.15, p = 0.09; 37.7, 95% CI: −10.1, 85.5, p = 0.12; −0.57, 95% CI: −0.97, −0.18, p = 0.005, respectively) compared to the control group. Conclusion: The 24-week home-based exercise program did not demonstrate beneficial effects on RKF in incident PD patients. Nonetheless, it may have an impact on reducing urinary protein levels and HbA1c percentages.
- 17 October 2024
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 45 (4) , 204-213
Impact of home-based exercise on residual kidney function in patients initiating peritoneal dialysis: A feasibility multicenter randomized controlled trial
Background: Although the impact of aerobic exercise (AE) and resistance training (RT) on peritoneal dialysis (PD) patients is well established, the impact of exercise programs on residual kidney function (RKF) has not been elucidated. Methods: Patients were randomly assigned to either the exercise ( n = 25) or control groups ( n = 30). Patients in the exercise group performed AE three times a week and RT twice a week at home for 24 weeks. The control group did not receive any specific intervention. The primary outcome was RKF, assessed by residual glomerular filtration rate (rGFR). Secondary outcomes included urinary protein levels, distance covered in the incremental shuttle walking test (ISWT), and glycated hemoglobin (HbA1c) percentages. Results: Linear mixed-effects models showed no significant changes in mean rGFR between the exercise and control groups at 12 weeks (−0.40; 95% confidence interval (CI): −2.17, 1.36; p = 0.65) and at 24 weeks (0.65; 95% CI: −1.15, 2.45; p = 0.48). There was a trend toward improvement in mean urinary protein level and ISWT results, and a significant decrease in mean HbA1c percentage at 24 weeks in the exercise group (−1.07, 95% CI: −2.29, 0.15, p = 0.09; 37.7, 95% CI: −10.1, 85.5, p = 0.12; −0.57, 95% CI: −0.97, −0.18, p = 0.005, respectively) compared to the control group. Conclusion: The 24-week home-based exercise program did not demonstrate beneficial effects on RKF in incident PD patients. Nonetheless, it may have an impact on reducing urinary protein levels and HbA1c percentages.
- 30 September 2024
- Published by Springer Nature in CEN Case Reports
- Vol. 14 (2) , 208-216
Effective calcineurin inhibitor treatment in adult-onset steroid-resistant nephrotic syndrome with a novel splice donor site variant of TRPC6: a case report
Transient receptor potential canonical 6 (TRPC6) variants, which were initially detected in adult-onset familial focal segmental glomerulosclerosis (FSGS), were also identified in pediatric-onset one. Here, we present a patient with adult-onset steroid-resistant nephrotic syndrome (SRNS) who harbored a likely pathogenic TRPC6 variant and partially responded to calcineurin inhibitors (CNIs). A 44-year-old woman with stable rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome was presented with nephrotic syndrome. Her renal biopsy results showed minor glomerular abnormalities. Upon admission, she was treated with steroids for around 4 weeks, but it was ineffective. After 1–2 weeks of cyclosporine A (CyA) administration, urine output increased, renal function improved without a decrease in proteinuria, and she was discharged. Her renal function was maintained for 2 months, but after a CyA dose reduction, she was again admitted to the hospital due to relapsing edema, decreased urine output, and worsening renal function. CyA was replaced by tacrolimus (TAC). A second renal biopsy showed nearly the same findings as the first except for tubulointerstitial lesions. After 1–2 weeks of TAC administration, urine output increased, and renal function improved. However, urinary protein levels did not decrease as before. After discharge, a whole exome analysis revealed a heterozygous splice donor site variant NM_004621.6;c.2644 + 1G > A in TRPC6. Genetic testing identified a novel splice donor site variant of TRPC6 in a patient with adult-onset SRNS, which prevented unnecessary steroid continuation. The safety and efficacy of CNI in TRPC6 glomerulopathy must be evaluated in future larger studies with longer follow-up.
- 30 September 2024
- Published by Springer Nature in CEN Case Reports
- Vol. 14 (2) , 208-216
Effective calcineurin inhibitor treatment in adult-onset steroid-resistant nephrotic syndrome with a novel splice donor site variant of TRPC6: a case report
Transient receptor potential canonical 6 (TRPC6) variants, which were initially detected in adult-onset familial focal segmental glomerulosclerosis (FSGS), were also identified in pediatric-onset one. Here, we present a patient with adult-onset steroid-resistant nephrotic syndrome (SRNS) who harbored a likely pathogenic TRPC6 variant and partially responded to calcineurin inhibitors (CNIs). A 44-year-old woman with stable rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome was presented with nephrotic syndrome. Her renal biopsy results showed minor glomerular abnormalities. Upon admission, she was treated with steroids for around 4 weeks, but it was ineffective. After 1–2 weeks of cyclosporine A (CyA) administration, urine output increased, renal function improved without a decrease in proteinuria, and she was discharged. Her renal function was maintained for 2 months, but after a CyA dose reduction, she was again admitted to the hospital due to relapsing edema, decreased urine output, and worsening renal function. CyA was replaced by tacrolimus (TAC). A second renal biopsy showed nearly the same findings as the first except for tubulointerstitial lesions. After 1–2 weeks of TAC administration, urine output increased, and renal function improved. However, urinary protein levels did not decrease as before. After discharge, a whole exome analysis revealed a heterozygous splice donor site variant NM_004621.6;c.2644 + 1G > A in TRPC6. Genetic testing identified a novel splice donor site variant of TRPC6 in a patient with adult-onset SRNS, which prevented unnecessary steroid continuation. The safety and efficacy of CNI in TRPC6 glomerulopathy must be evaluated in future larger studies with longer follow-up.
- Open Access
- 20 September 2024
- Published by Elsevier in Kidney Medicine
- Vol. 6 (11) , 100908
Acute Kidney Injury Associated With Red Yeast Rice (Beni-kōji) Supplement: A Report of Two Cases
- 20 September 2024
- Published by Elsevier in Kidney Medicine
- Vol. 6 (11) , 100908
Open AccessAcute Kidney Injury Associated With Red Yeast Rice (Beni-kōji) Supplement: A Report of Two Cases
- Open Access
- 18 July 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-7
Prognosis and characteristics of Corynebacterium exit site infection: a single-center retrospective study
Background: Corynebacterium is a rare but important cause of peritoneal dialysis (PD)-associated infection. A previous study reported that continued antibiotic use at the exit site is associated with increased Corynebacterium exit site infection (ESI), although the latest International Society of Peritoneal Dialysis guideline recommends its use. This study aims to verify the prognosis of Corynebacterium-associated PD-related infections, focusing on ESI. Methods: We conducted a single-center, retrospective study about ESI, tunnel infection (TI), and PD-associated peritonitis due to Corynebacterium between April 2018 and January 2023. We primarily examined the prognosis and characteristics of Corynebacterium ESI. Results: In this study, we included 125 patients with PD (mean age at PD onset: 69.4 ± 13.7 years, 71.2% male, 48% diabetic, mean estimated glomerular filtration rate at the introduction of PD 7.4 ± 2.6 ml/min/1.73 m2, total follow-up 179.6 patient dialysis year). Between April 2018 and January 2023, 191 cases of ESI, 62 cases of Corynebacterium ESI in 24 patients, 10 cases of TI, and 32 cases of PD-associated peritonitis were detected. In total, 16 of 24 patients with Corynebacterium-associated ESI tested positive for Corynebacterium multiple times in cultures against the exit site, with a maximum of eight times. The estimated glomerular filtration rate during PD introduction was relatively lower in patients with Corynebacterium-associated ESI than in patients without ESI (6.4 versus 7.9 mL/min/1.73 m2, respectively; P = 0.052). Although three of the Corynebacterium ESI cases progressed to TI, there were no cases that progressed directly to PD-associated peritonitis. Conclusions: Corynebacterium-associated ESI progresses to TI with a certain probability; however, it is thought that it rarely progresses to PD-associated peritonitis directly.
- 18 July 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-7
Open AccessPrognosis and characteristics of Corynebacterium exit site infection: a single-center retrospective study
Background: Corynebacterium is a rare but important cause of peritoneal dialysis (PD)-associated infection. A previous study reported that continued antibiotic use at the exit site is associated with increased Corynebacterium exit site infection (ESI), although the latest International Society of Peritoneal Dialysis guideline recommends its use. This study aims to verify the prognosis of Corynebacterium-associated PD-related infections, focusing on ESI. Methods: We conducted a single-center, retrospective study about ESI, tunnel infection (TI), and PD-associated peritonitis due to Corynebacterium between April 2018 and January 2023. We primarily examined the prognosis and characteristics of Corynebacterium ESI. Results: In this study, we included 125 patients with PD (mean age at PD onset: 69.4 ± 13.7 years, 71.2% male, 48% diabetic, mean estimated glomerular filtration rate at the introduction of PD 7.4 ± 2.6 ml/min/1.73 m2, total follow-up 179.6 patient dialysis year). Between April 2018 and January 2023, 191 cases of ESI, 62 cases of Corynebacterium ESI in 24 patients, 10 cases of TI, and 32 cases of PD-associated peritonitis were detected. In total, 16 of 24 patients with Corynebacterium-associated ESI tested positive for Corynebacterium multiple times in cultures against the exit site, with a maximum of eight times. The estimated glomerular filtration rate during PD introduction was relatively lower in patients with Corynebacterium-associated ESI than in patients without ESI (6.4 versus 7.9 mL/min/1.73 m2, respectively; P = 0.052). Although three of the Corynebacterium ESI cases progressed to TI, there were no cases that progressed directly to PD-associated peritonitis. Conclusions: Corynebacterium-associated ESI progresses to TI with a certain probability; however, it is thought that it rarely progresses to PD-associated peritonitis directly.